CO5611095A2 - Composicion farmaceutica que comprende n-((1-butil-4- piperidinil)metil)-3,4-dihidro-2h-(1,3)oxazino(3,2-a)indol -10-carboxamida o sal de la misma, y procedimiento para la misma que comprende granulacion en seco - Google Patents

Composicion farmaceutica que comprende n-((1-butil-4- piperidinil)metil)-3,4-dihidro-2h-(1,3)oxazino(3,2-a)indol -10-carboxamida o sal de la misma, y procedimiento para la misma que comprende granulacion en seco

Info

Publication number
CO5611095A2
CO5611095A2 CO04078329A CO04078329A CO5611095A2 CO 5611095 A2 CO5611095 A2 CO 5611095A2 CO 04078329 A CO04078329 A CO 04078329A CO 04078329 A CO04078329 A CO 04078329A CO 5611095 A2 CO5611095 A2 CO 5611095A2
Authority
CO
Colombia
Prior art keywords
same
salt
oxazino
carboxamide
methyl
Prior art date
Application number
CO04078329A
Other languages
English (en)
Inventor
Philip Christopher Buxton
Elizabeth Groves Sharon
Thomson Seona
Marinus Johannes Van Schien Dick
Kenneth Trevor Yeates
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0203528A external-priority patent/GB0203528D0/en
Priority claimed from GB0203526A external-priority patent/GB0203526D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO5611095A2 publication Critical patent/CO5611095A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1.- Un procedimiento para preparar una composición farmacéutica que comprende N-[(1-nbutil-4-piperidinil)metil]-3,4-dihidro-2H[1,3]oxazino[3,2-a]indol-10-carboxamida (SB 207266) o una sal farmacéuticamente aceptable de la misma, en combinación con uno o más excipientes farmacéuticamente aceptables, el procedimiento comprendiendo formar la SB 207266 completa o parte de la misma o la sal de la misma, en gránulos mediante un procedimiento de granulación en seco, y en donde la SB 207266 o la sal de la misma está presente en la composición en por lo menos 4% en peso, en peso de la composición.2.- El procedimiento de conformidad con la reivindicación 1, caracterizado además porque el procedimiento de granulación en seco es un procedimiento en el cual se forman gránulos totalmente en ausencia de un solvente de granulación aplicado externamente.3.- El procedimiento de conformidad con cualquier reivindicación anterior, caracterizado además porque el procedimiento de granulación en seco comprende compresión y compactación de la SB 207266 o la sal de la misma.
CO04078329A 2002-02-14 2004-08-11 Composicion farmaceutica que comprende n-((1-butil-4- piperidinil)metil)-3,4-dihidro-2h-(1,3)oxazino(3,2-a)indol -10-carboxamida o sal de la misma, y procedimiento para la misma que comprende granulacion en seco CO5611095A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0203528A GB0203528D0 (en) 2002-02-14 2002-02-14 Process and composition
GB0203526A GB0203526D0 (en) 2002-02-14 2002-02-14 Process and composition

Publications (1)

Publication Number Publication Date
CO5611095A2 true CO5611095A2 (es) 2006-02-28

Family

ID=27736214

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04078329A CO5611095A2 (es) 2002-02-14 2004-08-11 Composicion farmaceutica que comprende n-((1-butil-4- piperidinil)metil)-3,4-dihidro-2h-(1,3)oxazino(3,2-a)indol -10-carboxamida o sal de la misma, y procedimiento para la misma que comprende granulacion en seco

Country Status (22)

Country Link
US (1) US20050075335A1 (es)
EP (1) EP1476136B1 (es)
JP (1) JP2005523276A (es)
KR (1) KR100967782B1 (es)
AT (1) ATE329581T1 (es)
AU (1) AU2003202058B2 (es)
BR (1) BR0307666A (es)
CA (1) CA2475659A1 (es)
CO (1) CO5611095A2 (es)
CY (1) CY1106148T1 (es)
DE (1) DE60306120T2 (es)
DK (1) DK1476136T3 (es)
ES (1) ES2263949T3 (es)
HK (1) HK1072359A1 (es)
IS (1) IS2393B (es)
MX (1) MXPA04007857A (es)
NO (1) NO20043834L (es)
NZ (1) NZ534333A (es)
PL (1) PL206544B1 (es)
PT (1) PT1476136E (es)
RU (1) RU2329789C2 (es)
WO (1) WO2003068193A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
CA2406592C (en) * 2002-10-04 2003-09-30 Duchesnay Inc. Method of preparing pharmaceutical dosage forms containing multiple active ingredients
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
KR20090007622A (ko) * 2006-05-04 2009-01-19 노파르티스 아게 약학 조성물을 제조하기 위한 가열 롤러 압축 방법
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
ES2449074T3 (es) * 2007-06-22 2014-03-18 Bristol-Myers Squibb Holdings Ireland Composiciones en forma de comprimidos que contienen atazanavir
RU2471356C2 (ru) * 2007-07-31 2013-01-10 Карджилл, Инкорпорейтед Декстроза для прямого прессования
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
TWI461213B (zh) 2009-11-05 2014-11-21 Fmc Corp 作為藥物賦形劑之微晶纖維素及磷酸鈣之組合物
TW201129386A (en) * 2009-11-05 2011-09-01 Fmc Corp Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
RU2564922C2 (ru) * 2011-04-19 2015-10-10 Григорий Яковлевич ЛЕГИН Композиция для изготовления спороцидных композиций надуксусной кислоты, способ (варианты) и набор для его осуществления
US9606054B2 (en) 2013-09-30 2017-03-28 Advantest Corporation Methods, sampling device and apparatus for terahertz imaging and spectroscopy of coated beads, particles and/or microparticles
US9417181B2 (en) 2014-05-08 2016-08-16 Advantest Corporation Dynamic measurement of density using terahertz radiation with real-time thickness measurement for process control
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
WO2016126012A1 (en) * 2015-02-05 2016-08-11 Boryung Pharmaceutical Co., Ltd Tablet and method of preparing the same
CN104945303B (zh) * 2015-06-15 2017-09-29 浙江工业大学 3‑烯基吲哚类化合物的制备方法
PE20221838A1 (es) * 2020-04-24 2022-11-29 Astrazeneca Ab Formulaciones farmaceuticas
KR102499289B1 (ko) * 2022-04-15 2023-02-14 주식회사 비에스앤코 가루치약의 제조방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3134719A (en) * 1962-04-05 1964-05-26 American Cyanamid Co Calcium phosphates in tablet compressing
US5066441A (en) * 1980-12-12 1991-11-19 Rhone-Poulenc Basic Chemicals Co. Process for compacting a calcium phosphate composition
US4597969A (en) * 1982-04-05 1986-07-01 Merck Sharp & Dohme Stabilization of unstable drugs or food supplements
US4713245A (en) * 1984-06-04 1987-12-15 Mitsui Toatsu Chemicals, Incorporated Granule containing physiologically-active substance, method for preparing same and use thereof
US5055307A (en) * 1988-12-29 1991-10-08 Asahi Kagaku Kogyo Kabushiki Kaisha Slow release drug delivery granules and process for production thereof
US5861172A (en) * 1991-05-08 1999-01-19 Laboratorios Beecham Sa Pharmaceutical formulations of compacted granulates of β-lactam antibiotics
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
AP401A (en) * 1992-03-12 1995-08-29 Smithkline Beecham Plc Condensed indole derivatives as 5H4-receptor antagonists.
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
DE4418837A1 (de) * 1994-05-30 1995-12-07 Bayer Ag Thermisches Granulierverfahren
FR2740357B1 (fr) * 1995-10-25 1997-11-28 Rhone Poulenc Chimie Granules redispersables dans l'eau comprenant une matiere active sous forme liquide et un tensio-actif non ionique du type alcoxyles
CA2418904A1 (en) * 2000-08-07 2002-02-14 Laboratoire Glaxosmithkline S.A.S. Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation
EP1313481B1 (en) * 2000-08-08 2007-09-26 Smithkline Beecham Plc Pharmaceutical composition comprising condensed indole compound
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
US6666298B2 (en) * 2001-11-21 2003-12-23 John Volkman Hanging scaffold support

Also Published As

Publication number Publication date
WO2003068193A1 (en) 2003-08-21
AU2003202058A1 (en) 2003-09-04
RU2004127450A (ru) 2005-04-10
EP1476136B1 (en) 2006-06-14
JP2005523276A (ja) 2005-08-04
PL371963A1 (en) 2005-07-11
MXPA04007857A (es) 2004-10-15
IS2393B (is) 2008-08-15
US20050075335A1 (en) 2005-04-07
DE60306120D1 (de) 2006-07-27
ES2263949T3 (es) 2006-12-16
DK1476136T3 (da) 2006-10-09
CY1106148T1 (el) 2011-06-08
AU2003202058B2 (en) 2009-05-28
NZ534333A (en) 2006-05-26
RU2329789C2 (ru) 2008-07-27
KR100967782B1 (ko) 2010-07-05
CA2475659A1 (en) 2003-08-21
BR0307666A (pt) 2005-01-11
PT1476136E (pt) 2006-10-31
ATE329581T1 (de) 2006-07-15
DE60306120T2 (de) 2006-11-09
IS7398A (is) 2004-08-12
NO20043834L (no) 2004-10-26
EP1476136A1 (en) 2004-11-17
KR20040097996A (ko) 2004-11-18
PL206544B1 (pl) 2010-08-31
HK1072359A1 (en) 2005-08-26

Similar Documents

Publication Publication Date Title
CO5611095A2 (es) Composicion farmaceutica que comprende n-((1-butil-4- piperidinil)metil)-3,4-dihidro-2h-(1,3)oxazino(3,2-a)indol -10-carboxamida o sal de la misma, y procedimiento para la misma que comprende granulacion en seco
ES2522567T3 (es) Composición farmacéutica que comprende amlodipino y losartán
DK2158213T3 (da) VM23 og VM24, to skorpionpeptider, som blokerer humane T-lymphosyt kaliumkanaler (sub-type KV1.3) med høj selektivitet.
AR050615A1 (es) Composiciones farmaceuticas para la administracion oral
BR122012030846B8 (pt) composição farmacêutica não aquosa para uso dermatológico compreendendo calcipotriol e pelo menos um corticoesteróide, e, uso da mesma
BRPI0618380A2 (pt) combinação farmacêutica e seu uso
SE8303531D0 (sv) Farmaceutisk komposition
GT200600001A (es) Uso de colorantes de cianina para el diagnostico de enfermedades proliferativas
UY29771A1 (es) Nueva forma cristalina
AR049635A1 (es) (1r,2s,5s)-n-((1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil)-3-((2s)-2-((((1,1-dimetiletil)amino)carbonil)amino)-3,3-dimetil-1-oxobutil)-6,6-dimetil-3-azabiciclo(3.1.0)hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de la hepatitis c
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
BRPI0416752B8 (pt) composição farmacêutica, uso de um ou mais compostos, e, compostos
BR0215175A (pt) Métodos para a granulação úmida de azitromicina
CO5650230A2 (es) Composiciones estables de atorvastatina preparadas con granulacion en humedo
BRPI0613664A8 (pt) antagonista de 3-lactamil fenilalanina,cisteína e serina vasopressina
HK1072009A1 (en) Pharmaceutical desmopressin composition as solid dosage form and method for manufacturing thereof.
FI3769765T3 (fi) Natriumalkyylisulfaattia sisältävä farmaseuttinen koostumus
EA200200831A1 (ru) Фармацевтическая композиция, включающая пеметрексед вместе с монотиоглицерином, l-цистеином или тиогликолевой кислотой
UY27727A1 (es) Nueva composicion farmacéutica-
AR018607A1 (es) Preparacion farmaceutica que en calidad de ingrediente activo contiene levotiroxina sodica, y un procedimiento para su preparacion
WO2007050353A3 (en) Tricyclic compounds useful as oxytocin receptor agonists
BRPI0503775A (pt) composição que compreende um amido parcialmente pré-gelatinizado e método de preparar o mesmo
ATE423848T1 (de) Auslösender rezeptor der an der natürlichen cytotoxizität der menschlichen natürlichen killerzellen (natural killer cells) beteiligt ist und antikörper die diesen rezeptor identifizieren
BR0306732A (pt) Tratamentos em combinação para doença alérgica compreendendo a administração de um anticorpo anti-ige e composto antialérgico
EA200300247A1 (ru) Фармацевтическая композиция, содержащая циталопрам

Legal Events

Date Code Title Description
FC Application refused